Literature DB >> 20425459

Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults.

Ryan Mattison1, Wendy Stock.   

Abstract

Acute lymphoblastic leukemia affects infants, children, adolescents, and adults. Although most children have a high likelihood of cure, outcomes in adults have much room for improvement. In between lies the adolescent and young adult population, not only in terms of age but also in clinical success rates. This review describes biology, prognostic factors, and treatment approaches in adolescents and young adults with acute lymphoblastic leukemia. Assessing the outcomes in adult and pediatric clinical trials that enroll adolescents and young adults can be especially useful in determining how best to treat these patients. Current new treatment strategies are also discussed.

Entities:  

Mesh：

Year:  2008        PMID： 20425459     DOI： 10.1007/s11899-008-0021-y

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  34 in total

1.  Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.

Authors:  H M Kantarjian; S O'Brien; T L Smith; J Cortes; F J Giles; M Beran; S Pierce; Y Huh; M Andreeff; C Koller; C S Ha; M J Keating; S Murphy; E J Freireich
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

Review 2.  Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia.

Authors:  James Nachman
Journal:  Br J Haematol       Date:  2005-07       Impact factor: 6.998

3.  The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties.

Authors:  J M Chessells; E Hall; H G Prentice; J Durrant; C C Bailey; S M Richards
Journal:  Leukemia       Date:  1998-04       Impact factor: 11.528

4.  Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia.

Authors:  W Stock; T Tsai; C Golden; C Rankin; D Sher; M L Slovak; M G Pallavicini; J P Radich; D H Boldt
Journal:  Blood       Date:  2000-04-01       Impact factor: 22.113

5.  High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St. Jude Total Therapy Study X.

Authors:  M Abromowitch; J Ochs; C H Pui; D Kalwinsky; G K Rivera; D Fairclough; A T Look; H O Hustu; S B Murphy; W E Evans
Journal:  Med Pediatr Oncol       Date:  1988

6.  Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.

Authors:  Elly Barry; Daniel J DeAngelo; Donna Neuberg; Kristen Stevenson; Mignon L Loh; Barbara L Asselin; Ronald D Barr; Luis A Clavell; Craig A Hurwitz; Albert Moghrabi; Yvan Samson; Marshall Schorin; Harvey J Cohen; Stephen E Sallan; Lewis B Silverman
Journal:  J Clin Oncol       Date:  2007-03-01       Impact factor: 44.544

7.  Young adults 16-21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment.

Authors:  J Nachman; H N Sather; J D Buckley; P S Gaynon; P G Steinherz; D G Tubergen; B C Lampkin; G D Hammond
Journal:  Cancer       Date:  1993-05-15       Impact factor: 6.860

8.  Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial.

Authors:  Xavier Thomas; Jean-Michel Boiron; Françoise Huguet; Hervé Dombret; Ken Bradstock; Norbert Vey; Tibor Kovacsovics; André Delannoy; Nathalie Fegueux; Pierre Fenaux; Aspasia Stamatoullas; Jean-Paul Vernant; Olivier Tournilhac; Agnès Buzyn; Oumedaly Reman; Christiane Charrin; Claude Boucheix; Jean Gabert; Véronique Lhéritier; Denis Fiere
Journal:  J Clin Oncol       Date:  2004-09-07       Impact factor: 44.544

9.  A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.

Authors:  R A Larson; R K Dodge; C P Burns; E J Lee; R M Stone; P Schulman; D Duggan; F R Davey; R E Sobol; S R Frankel
Journal:  Blood       Date:  1995-04-15       Impact factor: 22.113

10.  Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.

Authors:  A Reiter; M Schrappe; W D Ludwig; W Hiddemann; S Sauter; G Henze; M Zimmermann; F Lampert; W Havers; D Niethammer
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.